Psilera Inc. is a biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic-derived therapies focused on novel treatments for neuropsychiatric disorders.
The company is developing PSIL-006, a first-in-class neuroplastogen designed to provide therapeutic benefits of traditional psychedelic compounds while minimizing hallucinogenic effects and cardiovascular risks, with plans to advance the asset into first-in-human trials.